
At #AIDS2026‘s oral abstract session entitled “Loved by users, limited by systems: Qualitative insights into LAI-PrEP [Long-Acting Injectable Pre-Exposure Prophylaxis],” our SHIPmate, Dr. Rod Olete moderated the discussion in the panel, who all came from communities working to make long-acting prevention a reality everywhere.
Insights were brought by the experts, tackling the issues of convenience and discretion versus efficacy, injection discomfort, and even the adoption of LAI-PrEP in communities affected by conflict and displacement. The panel highly agreed that the real barriers for these HIV prevention options are structural—the concerns being cost, insurance, mobility, and stigma, and not personal reluctance.
As the Philippines prepares for the national rollout of the LAI-PrEP medication, lenacapavir, this year, the lesson from the session and the International AIDS Conference becomes clear: Access has to be built with the same intention as the science. Choice only means something if the system delivers it.











